Suppr超能文献

腹腔镜与开放根治性肾切除术治疗肾肿瘤(> 7 cm)的肿瘤学和围手术期结果:系统评价和比较结果的汇总分析。

Oncologic and perioperative outcomes of laparoscopic versus open radical nephrectomy for the treatment of renal tumor (> 7 cm): a systematic review and pooled analysis of comparative outcomes.

机构信息

Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, 637000, China.

Department of Urology, The Second Hospital of Lanzhou University, Lanzhou, 730030, China.

出版信息

World J Surg Oncol. 2023 Feb 6;21(1):35. doi: 10.1186/s12957-023-02916-y.

Abstract

OBJECTIVE

Systematic evaluation of the effectiveness and safety of laparoscopic radical nephrectomy (LRN) for renal tumor (>7 cm).

METHODS

The databases PubMed, Scopus, SinoMed, ScienceDirect, and Google Scholar were systematically searched for trials up to November 2022. The pooled results were evaluated by weighted mean difference (WMD), odds ratio (OR), and hazard ratio (HR).

RESULTS

This meta-analysis (18 trials) demonstrated that compared to open radical nephrectomy (ORN), LRN had a longer operative time (OT) (WMD=15.99, 95% CI: 6.74 to 25.24, p = 0.0007), lower estimated blood loss (EBL) (WMD = -237.07, 95% CI: -300.02 to -174.12, p < 0.00001), lower transfusion rates (OR = 0.37, 95% CI: 0.24 to 0.55, p < 0.00001), and shorter length of stay (LOS) (WMD = -2.95, 95% CI: -3.86 to -2.03, p < 0.00001). No statistically relevant differences were found in overall survival (OS) (HR = 1.04, 95% CI: 0.81 to 1.35, p = 0.76), cancer-specific survival (CSS) (HR = 1.28, 95% CI: 0.97 to 1.68, p = 0.08), progression-free survival (PFS) (HR = 1.20, 95% CI 0.97 to 1.48, p = 0.1), recurrence-free survival (RFS) (OR = 1.27, 95% CI: 0.89 to 1.81, p = 0.56), local recurrence rate (OR = 0.85, 95% CI: 0.42 to 1.71, p = 0.65), and intraoperative and postoperative complications.

CONCLUSION

For patients with renal tumors (> 7 cm), LRN has specific perioperative advantages over ORN (LOS, EBL, and transfusion rates). However, the OT was prolonged in the LRN group. In addition, no differences in complication or oncological outcomes (OS, CSS, PFS, RFS, and local recurrence rate) were reported.

TRIAL REGISTRATION

PROSPERO CRD42022367114.

摘要

目的

系统评价腹腔镜根治性肾切除术(LRN)治疗肾肿瘤(>7cm)的有效性和安全性。

方法

系统检索PubMed、Scopus、SinoMed、ScienceDirect 和 Google Scholar 数据库,检索时间截至 2022 年 11 月。采用加权均数差(WMD)、比值比(OR)和风险比(HR)评估汇总结果。

结果

本荟萃分析(18 项研究)显示,与开放根治性肾切除术(ORN)相比,LRN 的手术时间(OT)更长(WMD=15.99,95%CI:6.74 至 25.24,p=0.0007),估计失血量(EBL)更少(WMD=-237.07,95%CI:-300.02 至-174.12,p<0.00001),输血率更低(OR=0.37,95%CI:0.24 至 0.55,p<0.00001),住院时间(LOS)更短(WMD=-2.95,95%CI:-3.86 至-2.03,p<0.00001)。两组的总生存(OS)(HR=1.04,95%CI:0.81 至 1.35,p=0.76)、癌症特异性生存(CSS)(HR=1.28,95%CI:0.97 至 1.68,p=0.08)、无进展生存(PFS)(HR=1.20,95%CI 0.97 至 1.48,p=0.1)、无复发生存(RFS)(OR=1.27,95%CI:0.89 至 1.81,p=0.56)、局部复发率(OR=0.85,95%CI:0.42 至 1.71,p=0.65)和术中术后并发症发生率无统计学差异。

结论

对于肾肿瘤(>7cm)患者,LRN 与 ORN 相比具有特定的围手术期优势(LOS、EBL 和输血率)。然而,LRN 组的手术时间延长。此外,在并发症或肿瘤学结局(OS、CSS、PFS、RFS 和局部复发率)方面未报告差异。

试验注册

PROSPERO CRD42022367114。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/916f/9901136/d8ff8a26b1a2/12957_2023_2916_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验